---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-149306"
form_type: "8-K"
ticker: null
cik: "0001501756"
company_name: "Adverum Biotechnologies, Inc."
filed_at: "2023-05-19T23:59:59+00:00"
generated_at: "2026-06-14T19:43:04.630863+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Adverum transfers to Nasdaq Capital Market; gets Nov 13 deadline for $1 bid compliance

## Summary
- Approved transfer from Nasdaq Global Market to Capital Market, effective May 22, 2023.
- Granted additional 180-day grace period until November 13, 2023 to regain $1.00 minimum bid price.
- Must have closing bid price at least $1.00 for ten consecutive business days during grace period.
- Plans reverse stock split to regain compliance; proxy statement filed for shareholder vote.
- Failure to comply by Nov 13 may lead to delisting and trading on OTC markets.

## SEC filing metadata
- accession: 0001193125-23-149306
- form_type: 8-K
- cik: 0001501756
- company_name: Adverum Biotechnologies, Inc.
- filed_at: 2023-05-19T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501756/000119312523149306/0001193125-23-149306-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501756/000119312523149306/d512702d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-149306
- JSON: https://secwatch.observer/filing/0001193125-23-149306.json
- Plain text: https://secwatch.observer/filing/0001193125-23-149306.txt

## Key facts
- Listing & Compliance Notices
  Adverum Biotechnologies, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1), 5810(c)(3)(A)
  source text: May 18, 2023, the Company received approval from the Listing Qualifications Department of Nasdaq to transfer the listing of the Company’s common stock from the Nasdaq Global Market to the Nasdaq Capital Market (the “Approval”). The Company’s securities will be transferred to the Capital Market at the opening of business on May 22, 2023. The Company’s common stock will continue to trade under the symbol “ADVM.” The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market, but with less stringent listing requirements, although listed companies must meet certain
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501756/000119312523149306/0001193125-23-149306-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.